Both in Biotechnology
Tarsus Pharmaceuticals vs Recursion Pharmaceuticals
Over the past year TARS returned +4.1% and RXRX returned −32.4%; their daily moves had a correlation of 0.27.
TARS +4.1% RXRX −32.4%Growth of $1, one year, split-adjusted
| Metric | TARS | RXRX |
|---|---|---|
| Price | $72.64 | $3.68 |
| Market cap | $3.40B | $2.20B |
| Today | −0.93% | −3.92% |
| 1 month | −2.4% | −23.0% |
| 6 months | +11.7% | +9.2% |
| Year to date | −11.3% | −10.0% |
| 1 year | +5.6% | −33.3% |
| Revenue growth (YoY) | +69.4% | +258.5% |
| Gross margin | 93.0% | 45.9% |
| Net margin | −10.7% | −641.6% |
| P/E (TTM) | — | — |
| Price / sales | 5.6× | 32.2× |
| Net cash | $376.9M | $538.0M |
| Dividend yield | — | — |
| Volatility (60d) | 46.1% | 95.4% |
| Short % of float | 15.3% | 37.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).